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OBJECTIVES: The Proﬁle of Mood States (POMS) is a widely
used instrument designed to assess current mood states and
changes. It has been frequently used to assess a variety of
patients, but its psychometric properties have never been evalu-
ated in postmenopausal women. The objective of this analysis
was to examine the reliability and validity of the POMS using
data from postmenopausal women with moderate-to-severe
hot ﬂushes (HF). METHODS: Postmenopausal women with
50 HF/wk were enrolled in a multicenter, randomized, double-
blind, placebo-controlled study of the efﬁcacy and safety of des-
venlafaxine succinate (DVS) to control vasomotor symptoms
(VMS). Subjects (N = 541) were asked to complete daily HF and
sleep diaries, and at baseline and week 12 the POMS, and Greene
Climacteric Scale (GCS), providing unique and valuable data
sources to validate the criteria and discriminant validity of
POMS. Floor and ceiling effects were explored, as well as sub-
scale internal consistency. Conﬁrmatory factor analysis was con-
ducted to investigate construct validity. Finally, the POMS’s
stability and responsiveness to change was established through
known-groups comparisons of change over time. RESULTS:
POMS demonstrated excellent baseline internal consistency
(Cronbach’s alpha range 0.84–0.94) across the 6 subscales and
Total POMS score; however, some items suffered ﬂoor effects.
Results from the conﬁrmatory factor analysis were supportive of
the second order interpretation (RMSEA = 0.07). Correlations
with GCS, HF, and sleep measures provided consistent criteria
and discriminant validity. For women with POMS scores better
than the female norms, there was little change at week 12 in both
groups (stability) but marked improvement in DVS groups
among women worse than the norm (responsiveness). CON-
CLUSION: Our data demonstrate the reliability and validity of
the 6 POMS subscales and the Total POMS score to measure
mood among postmenopausal women with moderate-to-severe
HF.
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OBJECTIVES: Describe the characteristics of women seeking
treatment for symptoms of stress urinary incontinence (SUI) and
to investigate their association with generic quality of life (QOL).
METHODS: Stress Urinary Incontinence Treatment Study
(SUIT) is a 12-month, observational study in four European
countries, evaluating cost-effectiveness of duloxetine compared
to other forms of non-surgical intervention in the treatment of
symptoms of SUI. Baseline data is presented. A total of 431
physicians observed women seeking treatment for their SUI and
recorded the care provided and the outcomes of that care at
enrolment, and 3, 6 and 12 months later. The impact of SUI on
QOL was assessed using the EuroQol (EQ-5D). Multivariate
linear regression was performed on the EQ-5D health state
index. RESULTS: A total of 3762 women were enrolled into
SUIT; the largest patient group from Germany. The majority
were post-menopausal, with a mean age of 58.0 years, were
not current smokers and tended to be overweight (mean
BMI = 27.7), with at least one co-morbidity. Health state index
(HSI) scores were signiﬁcantly (p < 0.0001 for all factors except
previous surgery, where p = 0.049) and independently inﬂuenced
by, in order of the strength of the association, the total number of
incontinence episodes, presence of co-morbidity(ies) affecting
QoL, socio-economic status, presence of co-morbidity(ies) affect-
ing incontinence, BMI, urinary incontinence (UI) subtype and
previous surgery. Each additional incontinence episode was asso-
ciated with a decrease in HSI score of 0.002 points, each comor-
bidity affecting QoL was associated with a HSI score reduction of
0.072 points and each comorbidity directly affecting inconti-
nence was associated with a reduction of 0.040 points. Mixed
Urinary Incontinence had a greater negative inﬂuence on HSI
score than pure SUI. CONCLUSION: This analysis describes the
characteristics of patients at the enrolment visit, and demon-
strates that the number of incontinence episodes has the greatest
impact on the EQ-5D Health State Scores.
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OBJECTIVES: Active case ﬁnding for osteoporosis is increas-
ingly popular. However, it is not known if subjects, once identi-
ﬁed as having osteoporosis, are willing to take preventive drug
treatment, and what determines this willingness. We investigated
patients’ preferences for preventive osteoporosis drug treatment
in a discrete choice experiment. METHODS: A discrete choice
experiment (DCE) was administered to community dwelling
females aged over 60 years (n = 120; including women with high
fracture risk (n = 60)), identiﬁed by osteoporosis case ﬁnding in
34 GP-practices in and around Rotterdam. We investigated the
effects on acceptance of preventive drug treatment of treatment
effectiveness, side effects (nausea), total treatment duration,
route of drug administration, and costs. The relative importance
of the treatment attributes, the trade-offs that elderly women are
willing to make between these attributes, and willingness to pay
were estimated using conditional logistic regression analysis.
RESULTS: All treatment attributes were important to respon-
dents (p < 0.05). Absence of side effects of drug treatment was
the most important treatment attribute of treatment acceptance.
The negative utility of side effects such as nausea was totally
compensated for when the drug reduced the relative lifetime risk
of hip fracture by 35% or more. Women were prepared to pay an
out-of-pocket contribution if the treatment was coherent with
their preference. CONCLUSION: Women identiﬁed by active
osteoporosis case ﬁnding are highly prepared to adhere to pre-
ventive drug treatment, even if side effects (nausea) are expected
and some out-of-pocket contribution is required.
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